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Fifty-one CT-guided percutaneous fine-needle aspiration biopsies (PFNAB) were performed
on 46 consecutive patients over 15 months. Cytologies were obtained to identify primary or
secondary malignancy in the abdomen, pelvis, retroperitoneum, bone, and paraspinal region.
Adequate cytologic material was obtained in 50 of 51 biopsies. There were 29 true-positive, 0
false-positive, 12 true-negative, and two false-negative cases with an overall accuracy rate of 95
percent. There was one minor complication, mesenteric hemorrhage, which did not require
transfusion. Fifteen of the 51 biopsies were performed on outpatients. The procedure is an
accurate, safe, and cost-effective nonsurgical means of diagnosing primary or secondary
malignancy.
INTRODUCTION
Percutaneous fine-needle aspiration biopsy (PFNAB) under computed tomographic
(CT) guidance has proved to be a widely accepted method ofdocumenting malignancy
[1-21]. Refinements in technique, experience with the procedure, and improvements
in CT scanners have permitted a high degree of accuracy [1-3,8,9,16,18,21]. We
present our experience over a 15-month period with this technique.
MATERIALS AND METHODS
Between January 1984 and March 1985, 46 consecutive patients had PFNAB at
Yale-New Haven Hospital. Lesions biopsied were initially detected by CT or referred
to CT after prior clinical or radiologic examinations demonstrated an abnormality.
Lesions ranged in size from 1-10 cm. Biopsies were performed to rule out malignancy.
Lung biopsies and abscess aspirations were excluded from this series. The patient
population consisted of 28 males and 18 females with a mean age of 62 years and an
age range of 23-85 years. Thirty-six biopsies were performed on inpatients and 15 on
outpatients. Twenty-eight patients had a known primary prior to the biopsy. These
were as follows: colon carcinoma, seven; lymphoma, six; ovarian carcinoma, three;
carcinoma of the cervix, three; renal cell carcinoma, two; breast carcinoma, two;
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FIG. 1. Metastatic cervi-
cal carcinoma. CT scan
demonstrating needle tip
(black arrow) in para-aortic
lymph node(n). Note that in
this prone patient the access
route avoids the kidney (k)
and aorta (a). Curved white
arrow shows a needle-tip
artifact.
hepatoma, one; prostatic carcinoma, one; endometrial carcinoma, one; vulvar carci-
noma, one; and leukemia, one. Sites biopsied were: intraperitoneal, ten; retroperitone-
al, seven; presacral space, seven; liver, six; pancreas, six; bone/paraspinal, six; kidney,
three; and adrenal, one.
The biopsy was performed on either the GE 9800 or 8800 CT scanner. Prior to
biopsy, informed consent, a normal prothrombin time, partial thromboplastin time,
and platelet count were obtained for all patients. In some cases, intramuscular
meperidine hydrochloride 50-75 mg was given before the biopsy.
CT was used to determine the depth of the mass, internal relation of the mass to
other structures, and the safest needle path. After sterile preparation and local
anesthesia, the needle was placed within the lesion and the exact site of the needle tip
was documented by a CT scan before any aspiration took place (Fig. 1). Twenty-two-
or 20-gauge Franseen needles were used in all cases. Bowel was freely traversed but
major vessels were avoided (Figs. 4,5). Within our cytology laboratory, smear
preparations are stained immediately with Papanicolaou's stain and interpreted while
a patient is undergoing the aspiration biopsy. Excessive material and fluid from a
saline washout or purge ofthe needle is collected and centrifuged into an aggregate of
cells or cell block. Cell blocks are processed by formalin fixation and paraffin
embedding overnight and are stained with hematoxylin and eosin the following day
(Fig. 3). Cytology results from the slides were obtained in 30 minutes; cell block slides
were available within 24 hours.
The cytology aspirates were retrospectively reviewed by a single pathologist (KB)
without knowledge ofclinical outcome. Each case was assigned to one ofthe following
five categories: (1) inadequate material; (2) no evidence of tumor; (3) atypical cells,
probably reactive (non-neoplastic); (4) atypical cells, suspicious for malignant tumor
(probably neoplastic); and (5) malignant cells present. All diagnoses which had
originally been rendered as negative or positive diagnosis were confirmed (category 2
or category 5 ). Cases originally interpreted as indefinite were assigned to categories 3
or 4. Standard cytologic criteria were employed to diagnose malignant cells as
illustrated in selected cases (Fig. 2). A biopsy was considered positive for tumor ifthe
cytology report was atypical cells, suspicious for malignant tumor (category 4 ) or






FIG. 2. Representative pathologicspecimens. A Small cell carcinoma originating from uterine cervix
(see Fig. 1). Nuclei demonstrate irregular shapes with polyploidy and molding. Chromatin distribution is
coarse and relatively uniform. B High grade transitional cell carcinoma aspirated from retroperitoneal
lymph nodes (see Fig. 7). The nuclei show minimal differentiation with coarse clumping of chromatin,
irregular thickness and contour of the nuclear envelope, and variation in size. Moderate amounts of finely
granular cytoplasm surround the nuclei. C Adenocarcinoma, poorly differentiated, ofpancreatic origin
(see Fig. 5). Nuclei show marked variation in size and shape, molding irregular prominent nucleoli, and
abnormal chromatin dispersal. D Adenocarcinoma of pulmonary origin (see Fig. 6). Nuclei are
characterized by multiple discrete nucleoli, variation in size, and coarse chromatin dispersal. E Papil-
lary adenocarcinoma of ovarian origin (see Fig. 4). Cohesive cluster of cells with moderate vascular
cytoplasm and crowded irregular nuclei with prominent nucleoli and peripheral clumping ofchromatin (all
preparations x 1,000, Papanicolaou stain).
A negative biopsy was considered a true-negative if: (a) surgery revealed no evidence
of tumor; (b) one-year clinical follow-up was negative for evidence of tumor; or (c)
one-year CT follow-up showed no change in the biopsy mass. A negative biopsy was
considered false-negative if: (a) surgery proved there was a tumor at the biopsy site; or







FIG. 3. Smears, cell block, and histologic
preparation of high-grade papillary serous
carcinoma of ovarian origin (see Fig.
4). A Smear demonstrating two malig-
nant cells characterized by large irregular
nuclei, prominent nucleoli, and clumped
chromatin (Papanicolaou stain, x
1,000). B Centrifuged cell block of
excess material which has been paraffin-
embedded. This allows concentration ofcells
that may be difficult to evaluate in quantity
on the smears (H&E, x 1,000). C His-
tologic preparation showing papillary serous
carcinoma in the lower field, and solid,
poorly differentiated carcinoma in the upper
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FIG. 4. CT scan of PFNAB of bowel mass (m) in patient with known ovarian primary revealing
metastatic disease. Note that bowel (b) is freely transgressed. Arrow indicates needle tip.
metastasis. A category listed as "inadequate study" was used for: (a) patients who did
not meet the biopsy criteria of three needle passes into an identifiable lesion on CT
scan; or (b) patients who have not had at least one-year clinical, surgical, or CT
follow-up.
Outpatients were instructed to arrange an escort home. The outpatients were
monitored in the department for three hours post-biopsy. The patient and escort were
instructed about possible complications.
RESULTS
Fifty of 51 biopsies (98 percent) in 46 patients had sufficient cytologic material.
There were 29 true-positives (TP), 12 true-negatives (TN), two false-negatives (FN),
no false-positives (FP), and three inadequate study (see later). Sensitivity was 94
percent. Specificity was 100 percent. Overall accuracy was 95 percent. Predictive
value of a positive biopsy was 100 percent, while predictive value of a negative biopsy
was 85 percent. The initial biopsy was correct in 40 of 43 patients (93 percent) with
adequate follow-up. Five patients had second biopsies. One initial biopsy that was
atypical and notdiagnostic oftumor was positive for tumor on the second biopsy. Three
patients had two negative biopsies that were later proven to be true-negative. One
person with two negative biopsies by CT guidance was later positive for tumor by
ultrasound-guided biopsy. Of the 28 patients with a known primary, 17 were
true-positives, nine true-negatives, one false-negative, and one inadequate study.
Seventeen of the 29 patients with true-positive results had known primary lesions
with biopsies that were consistent with metastasis from the primary (Fig. 4). The
remaining 12 true-positive biopsies were new diagnoses of cancer: pancreatic carci-
noma, four (Fig. 5) (one had the liver biopsied, demonstrating adenocarcinoma in a
I
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FIG. 5. CT scandemonstrating needlepassing through duodenum (d) into pancreatic head mass (m).The
biopsy revealed adenocarcinoma in the pancreas. The needle tip within the mass is demonstrated by the
arrow.
patient with a large pancreatic mass); renal carcinoma, two; lymphoma, two; hepato-
ma, one; transitional cell carcinoma, one; lung carcinoma (bone was biopsied), one
(Fig. 6); and colonic carcinoma, one. Nine of the 12 true-negatives had a known
primary but negative biopsies, which were later confirmed by surgery, one; CT
follow-up four; or clinical follow-up, seven.
Two patients had false-negative biopsies. One patient had a pancreatic mass and
retroperitoneal adenopathy seen on CT; three needle passes were performed, and
cytology was negative for tumor. Another biopsy was scheduled but not performed, due
to the patient's clinical status. Radiation therapy was initiated. A follow-up CT scan
has revealed an increase in the size ofthe pancreatic mass with new multiple lesions in
the liver. The second false-negative biopsy occurred in a patient with known endome-
trial cancer who had a non-uterine pelvic mass that was negative for tumor on two
separate CT-guided biopsies. Due to time constraints, a scheduled third CT-guided
biopsy was transferred to ultrasound. The ultrasound-guided biopsy was positive for
metastastic endometrial carcinoma.
Three patients were listed in the inadequate study category. Two patients did not
meet the criteria for adequate biopsies while the third patient has not had a one-year
clinical or CT follow-up. Onepatient with a pancreatic mass permitted only one needle
pass, which was negative. Although a tissue diagnosis of cancer has not been made, a
recent CT scan showed an increase in the size ofthe pancreatic mass and development
of liver lesions during the interval. The second patient had abdominal pain with a
negative CT examination. Since there was a strong clinical suspicion of a pancreatic
abnormality, an ERCP and angiogram were performed which were abnormal. Two
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FIG. 6. CT scan showing needle tip (arrow) in destructive right ileum lesion of patient with an unknown
primary. Cytology revealed poorly differentiated adenocarcinoma from a lung primary.
months later, another CT scan demonstrated no pancreatic mass. At the clinician's
request, three CT-guided needle passes in the region of the pancreatic head were
obtained and were negative for tumor. At surgery, a tumor was found in the liver,
which was consistent with a pancreatic or biliary carcinoma. Unfortunately, the
pancreas was not biopsied. The third patient with previous colon carcinoma presented
with a large pelvic mass that was negative for tumor on CT-guided, ultrasound-guided,
and surgical biopsy. Radiation therapy was initiated. One year follow-up is unavail-
able.
The only biopsy complication followed a pancreatic aspiration. After three passes
with a 22-gauge Franseen needle, mesenteric hemorrhage was noted on the CT scans.
The patient was admitted overnight for observation, and his course was uneventful.
The patient's blood pressure remained stable, and no transfusions were required.
Patient management was definitely affected by the biopsy results (Table 1). Of the
29 TP, only five, thus far, have had surgery. The two new cases of lymphoma needed
larger amounts of tissue for more specific histologic classification. The other three
patients underwent debulking surgery. Nineteen ofthe 29 TP did not have any surgery
but instead were treated with radiation and/or chemotherapy. The effect offive recent
TP biopsies on patient care is indeterminate at this time.
Twelvepatients had TN biopsies formalignant tumor. Onepatient had surgery after
two negative biopsies; surgical pathology was also negative. Three patients with
vertebral body destruction had biopsies negative for tumor; hence, they were treated
with antibiotics and clinically improved. Four patients continued their prior chemo-
therapy regimen without the need for surgical intervention. Clinical follow-up at one
year was negative for metastases. Four patients had follow-up CT scans showing no




Sites of Lesions Biopsied TP TN FP FN IF Total
Presacral 4 3 0 0 0 7
Abdominal/pelvic 8 0 0 1 1 10
Retroperitoneum 6 1 0 0 0 7
Liver 2 4 0 0 0 6
Pancreas 3 0 0 1 2 6
Renal 3 0 0 0 0 3
Bone 3 3 0 0 0 6
Adrenal 0 1 0 0 0 1
Total 29 12 0 2 3 46
TP, true-positive TN, true-negative
follow-up
FP, false-positive FN, false-negative IF, inadequate
DISCUSSION
CT-guided PFNAB is the most accurate method of performing biopsies [2,7,8].
Because of increased contrast and spatial resolution, modern scanners can accurately
guide needle placement for biopsy ofextremely small lesions (as small as 1 cm; see Fig.
7). CT has become the preferred method of PFNAB for lesions less than 3 cm in size
and deep lesions [1,2,4] not readily accessible to sonography. The advantages of CT
not only include clear definition ofthe lesion, access route, and needle-tip location, but
also the capability of identifying highly vascular lesions via the use of intravenous
FIG. 7. CT scan ofpatient in prone position to enable needle access to a 1 cm retroperitoneal lymph node
(curved white arrow) (non-pathologically enlarged by standard CT size criteria). Biopsy demonstrated




Organ % Literature [References] % Yale
Liver 83-99 [4-8, 18, 19] 100
Retroperitoneum (including renal) 78-100 [1-4, 7] 100
Presacral Not available 100
Bone, paraspinal 80-100 [1, 2, 10] 100
Abdomen/pelvic 75-100 [4, 5, 7, 9] 88
Pancreas 60-90 [1, 2, 4, 5, 7, 9] 75
contrast medium [4,7,16,18]. Our accuracy was 100 percent for presacral, renal, liver,
retroperitoneal, paraspinal, bone, and adrenal lesions, 88 percent for abdominal pelvic
lesions, and 75 percent for pancreatic lesions. As can be seen from Table 2, our overall
accuracy compares favorably with those in the literature.
The relatively lower accuracy of PFNAB of pancreatic masses is similar to results
obtained at surgery [2]. The difficulty in obtaining a positive tumor diagnosis is due to
the known inflammatory response which occurs with these tumors. Thus, despite exact
localization of the needle tip within the lesion, tissue must be obtained from various
areas to reduce sampling error. A biopsy of associated abdominal masses (e.g., liver
metastases) may yield a positive tumor diagnosis rather than a sole biopsy of the
primary pancreatic mass.
Reports ofaccuracy for the diagnosis oflymphoma range from 40 percent [7] to 75
percent [1]. Our accuracy was 100 percent (eight of eight patients). Recurrence was
documented in six patients with known lymphoma. Two new cases that were not
suspected prior to biopsy were diagnosed. Surgery was necessary to sub-type histologi-
cally these two patients. Our high accuracy may be attributable to utilization of
20-gauge needles in addition to the smaller 22-gauge needle, a state-of-the-art CT
scanner, and the expertise ofthe pathologist.
Both cytologic and histologic cores oftissue are sought when biopsies are performed.
We believe that needle selection depends on the clinical suspicion, safety, depth ofthe
access route, the lesion vascularity, amount of tissue needed, and expertise of the
pathologist. We routinely prepare smears stained by the Papanicolaou technique and
slides from centrifuged cell blocks in our laboratory. The former preparation allows
rapid interpretation during the procedure and may indicate a need for needle
reposition. The latter technique allows concentration of the material and more ready
application of histochemical and immunohistochemical techniques for tumor subclas-
sification. This is an overnight preparation which usually confirms the diagnosis
established based upon the smears. In our laboratory, however, about 1-2 percent of
cell blocks reveal diagnostic material following an acellular or negative smear the
preceding day. This finding requires deferment ofall negative smears until completion
ofthe cell block.
Clearly, PFNAB is an integral part of the diagnostic work-up of a patient with a
suspected mass. In an era ofcost-effective medical care, there is considerable incentive
for rapid diagnosis without hospitalization. To date, no method of in vivo tissue
characterization ofmasses has proved accurate enough to replace pathologicdiagnosis;
therefore, biopsy should be performed when a mass is identified. CT-guided biopsy is a
safe, fast, and accurate means to obtain pathological tissue for the diagnosis of
disease.
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